Stocks in news today

's wholly owned step-down subsidiary -- CuraTeQ Biologics s.r.o. has obtained marketing authorization from the European Commission for Dazublys, its trastuzumab biosimilar version. Earlier in April 2025, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Dazublys, recommending its marketing authorization. This is CuraTeQ’s third biosimilar to be approved by EMA after the approval of Dyrupeg in April 2025 and Zefylti in February 2025, and the fourth overall in the EU, alongside the approval of Bevqolva by the UK’s MHRA in December 2024. ’s subsidiary -- Biocon Biologics (BBL) has received marketing authorisation in the European Union (EU) for Vevzuo and Evfraxy biosimilars of Denosumab from the European Commission (EC). Vevzuo is authorised for the prevention of bone complications in adults with advanced cancer involving bone and the treatment of adults and skeletally mature adolescents with giant cell tumour (GCT) of bone. Evfraxy is authorised for the treatment of osteoporosis in men and postmenopausal women, the treatment of bone loss linked to hormone ablation in men with prostate cancer at increased risk of fractures or treatment of bone loss associated with long-term systemic glucocorticoid therapy in adults. ’ Wholly Owned Subsidiary -- Motilal Oswal Asset Management Company (MOAMC) has achieved a significant milestone with its Assets Under Management (AUM) crossing Rs 1.5 lakh crore across Mutual Funds (Active & Passive), Portfolio Management Services (PMS) and Category-III Alternative Investment Funds (AIFs). Over the past five years, MOAMC has delivered a robust 34% CAGR in AUM, rising from Rs 35,180 crore in June 2020. This growth is anchored in the AMC’s clear and consistent focus on high-quality, earnings-led growth investing.